Oncolytics Biotech

Oncolytics Biotech, based in San Diego, the United States, is a biotechnology company. Oncolytics Biotech develops immunotherapies for gastrointestinal and other cancers, centred on pelareorep, an investigational double-stranded RNA immunotherapeutic agent. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing Trifluridine Tipiracil in colorectal cancer, HR-positive / HER2-negative breast cancer, anal cancer and pancreatic ductal adenocarcinoma. The largest, NCT07280377 (A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab), plans to enrol 122 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.